



Ifu

PATENT APPLICATION  
File No: 03-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey  
R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V.  
Sivakumar, Margaret D. Moore  
Serial No. : 10/807,837  
Group Art Unit : 1646  
Examiner :  
Filed : March 24, 2004  
For : ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND  
METHODS OF USING IN INFLAMMATION

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence, comprising:

1. Information Disclosure Statement
2. PTO-1449 Form
3. 51 References
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on April 7, 2005.

  
\_\_\_\_\_  
Kim M. Goplen



PATENT APPLICATION  
File No: 03-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey  
R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V.  
Sivakumar, Margaret D. Moore  
Serial No. : 10/807,837  
Group Art Unit : 1646  
Examiner :  
Filed : March 24, 2004  
For : ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND  
METHODS OF USING IN INFLAMMATION  
Date Submitted : April 7, 2005

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Shelby J. Walker". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Shelby J. Walker  
Registration No. 45,192

**FORM PTO 1449** **U.S. DEPARTMENT OF COMMERCE**  
(REV 2-32) **PATENT AND TRADEMARK OFFICE**

File No. 03-02

Serial No.  
10/807,837

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
Wenfeng Xu et al.Filing Date:  
March 24, 2004

Group: 1646

Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,488,032	01/30/96	Dower et al.	514	2	
	A2	5,965,704	10/12/99	Lok et al.	530	350	
	A3	6,274,710	08/14/01	Dumoutier et al.	530	387.9	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A4	1191035	03/27/02	Europe			
	A5	WO01/40467	06/07/01	WIPO			
	A6	WO98/37193	08/27/98	WIPO			
	A7	WO01/36467	05/25/01	WIPO			
	A8	WO02/066647	08/29/02	WIPO			
	A9	WO02/024912	03/28/02	WIPO			
	A10	WO98/02542	01/22/98	WIPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A11		Dumoutier et al., "Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types," <i>J. Immunol.</i> 167:3545-3549, 2001.
	A12		Dumoutier, L et al., "Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22," <i>J. Immunol.</i> 166:7090-7095, 2001.
	A13		Kotenko et al., "Identification, Cloning, and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity," <i>J. Immunol.</i> 166:7096-7013, 2001.
	A14		Xu et al., "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist," <i>Proc. Nat. Acad. Sci.</i> 98:9511-9516, 2001.
	A15		Gruenberg et al., "A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta," <i>Genes and Immunity</i> 2:329-334, 2001.
	A16		Xie et al., "Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2-4 and IL-22R," <i>J. Biol. Chem.</i> 275(40):31335-31339, 2000.
	A17		Dumoutier et al., "Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9," <i>Journal of Immunology</i> 164: 1814-1819, 2000.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**FORM PTO 1449**  
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**

File No. 03-02

Serial No.  
10/807,837

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant(s):  
Wenfeng Xu et al.

Filing Date:  
March 24, 2004

Group: 1646

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A18	WO99/07848	02/18/99	WIPO		
	A19	WO00/73457	12/07/00	WIPO		
	A20	WO00/77037	12/21/00	WIPO		
	A21	WO00/24758	05/04/00	WIPO		
	A22	WO00/39161	07/06/00	WIPO		
	A23	WO00/65027	11/02/00	WIPO		
	A24	WO00/70049	11/23/00	WIPO		
	A25	WO01/16318	03/08/01	WIPO		
	A26	WO01/46422	06/28/01	WIPO		
	A27	WO01/98342	12/27/01	WIPO		
	A28	WO02/20569	03/14/02	WIPO		
	A29	WO02/072607	09/19/02	WIPO		
	A30	WO03/035096	05/01/03	WIPO		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A31	Dumoutier et al. "Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor," <i>Proc. Nat. Acad. Sci.</i> 97(18):10144-10149, 2000.
	A32	Dumoutier et al., IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes," <i>Genes and Immunity</i> . 1:488-494, 2000.
	A33	Xu, X. et al., EMBL Database, Chinese National Human Genome Center at Shanghai, 5 Oct. 2000: AV714177.
	A34	Incyte Pharmaceuticals, Inc. clone, 1999: SHLW01158999.
	A35	Wells, "Additivity of Mutational Effects In Proteins," <i>Biochemistry</i> 29(37):8509-8517, 1990.
	A36	Liu et al., "Expression Cloning and Characterization of a Human IL-10 Receptor," <i>J. Immunol.</i> 152:1821-1829, 1994.
	A37	Blumberg et al., "Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function," <i>Cell</i> 104:9-19, 2001.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**FORM PTO 1449**  
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**

File No. 03-02

Serial No.  
10/807,837

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant(s):  
Wenfeng Xu et al.

Filing Date:  
March 24, 2004

Group: 1646

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A38		Zhang et al., "Identification, Purification, and Characterization of a Soluble Interleukin (IL)-13-binding Protein," <i>J. Biochem.</i> 272:9474-9480, 1997.
	A39		Kotenko et al., "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes," <i>Oncogene</i> 19:2557-2565, 2000.
	A40		Kotenko et al., "Identification of the Functional Interleukin-22 (IL-22) Receptor Complex," <i>J. Biochem.</i> 276(4):2725-2732, 2001.
	A41		Wei et al., "Cloning and characterization of mouse IL-22 binding protein," <i>Genes and Immunity</i> 34:204-211, 2003.
	A42		Bork et al., "Go hunting in sequence databases but watch out for the traps," <i>TIG</i> 12(10):425-0426, 1996.
	A43		Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Research</i> 10:398-400, 2000.
	A44		Sempowski et al., "Subsets of Murine Lung Fibroblasts Express Membrane-Bound and Soluble IL-4 Receptors," <i>J. Immunol.</i> 152: 3606-3614, 1994.
	A45		Bork et al., "Predicting functions from protein sequences – where are the bottlenecks," <i>Nature Genetics</i> 18:313-318, 1998.
	A46		Parrish-Novak et al., "Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes," <i>J. Biochem</i> 277(49):47517-47523, 2002.
	A47		Uhlir et al., "Serum amyloid A, the major vertebrate acute-phase reactant," <i>Eur. J. Biochem.</i> 265:501-523, 1999.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

